WO2026078207A1 - Nouveaux ligands de liaison à l'arndb et leur utilisation en chromatographie d'affinité - Google Patents

Nouveaux ligands de liaison à l'arndb et leur utilisation en chromatographie d'affinité

Info

Publication number
WO2026078207A1
WO2026078207A1 PCT/EP2025/079283 EP2025079283W WO2026078207A1 WO 2026078207 A1 WO2026078207 A1 WO 2026078207A1 EP 2025079283 W EP2025079283 W EP 2025079283W WO 2026078207 A1 WO2026078207 A1 WO 2026078207A1
Authority
WO
WIPO (PCT)
Prior art keywords
dsrna
binding
seq
amino acid
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/079283
Other languages
English (en)
Inventor
Michael Niemeyer
Malte NEUDORF
Heike BOECKER
Hanna Bobolowski
Erik Fiedler
David HAVLIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navigo Proteins GmbH
Original Assignee
Navigo Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins GmbH filed Critical Navigo Proteins GmbH
Publication of WO2026078207A1 publication Critical patent/WO2026078207A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une nouvelle matrice de séparation par affinité qui comprend de nouveaux ligands de liaison pour l'ARN double brin (ARNdb) et l'utilisation de ladite matrice de séparation par affinité pour purifier des préparations d'acide ribonucléique. La présente invention concerne en outre un procédé de purification de préparations d'acide ribonucléique et un kit destiné à être utilisé dans un procédé de purification de préparations d'acide ribonucléique, mettant en oeuvre la nouvelle matrice de séparation par affinité. La présente invention concerne également un procédé de production d'une préparation d'ARN simple brin (ARNsb).
PCT/EP2025/079283 2024-10-11 2025-10-10 Nouveaux ligands de liaison à l'arndb et leur utilisation en chromatographie d'affinité Pending WO2026078207A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24206209.9 2024-10-11
EP24206209 2024-10-11

Publications (1)

Publication Number Publication Date
WO2026078207A1 true WO2026078207A1 (fr) 2026-04-16

Family

ID=93117234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/079283 Pending WO2026078207A1 (fr) 2024-10-11 2025-10-10 Nouveaux ligands de liaison à l'arndb et leur utilisation en chromatographie d'affinité

Country Status (1)

Country Link
WO (1) WO2026078207A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077205A1 (fr) * 1999-06-11 2000-12-21 Barber Glen N Facteurs nucleaires humains associes a l'arn bicatenaire (nfar)
US20030068803A1 (en) * 2001-01-12 2003-04-10 Robin Reed Purification of functional ribonucleoprotein complexes
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2013102203A1 (fr) 2011-12-30 2013-07-04 Cellscript, Inc. FABRICATION ET UTILISATION D'ARNss SYNTHÉTISÉS IN VITRO POUR INTRODUCTION DANS DES CELLULES MAMMALIENNES AFIN D'INDUIRE UN EFFET BIOLOGIQUE OU BIOCHIMIQUE
CN106191036A (zh) * 2016-08-08 2016-12-07 吴江近岸蛋白质科技有限公司 Rna结合蛋白在提取核酸中的应用及提取方法
WO2017182524A1 (fr) 2016-04-22 2017-10-26 Biontech Rna Pharmaceuticals Gmbh Procédés de production d'arn simple brin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077205A1 (fr) * 1999-06-11 2000-12-21 Barber Glen N Facteurs nucleaires humains associes a l'arn bicatenaire (nfar)
US20030068803A1 (en) * 2001-01-12 2003-04-10 Robin Reed Purification of functional ribonucleoprotein complexes
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2013102203A1 (fr) 2011-12-30 2013-07-04 Cellscript, Inc. FABRICATION ET UTILISATION D'ARNss SYNTHÉTISÉS IN VITRO POUR INTRODUCTION DANS DES CELLULES MAMMALIENNES AFIN D'INDUIRE UN EFFET BIOLOGIQUE OU BIOCHIMIQUE
WO2017182524A1 (fr) 2016-04-22 2017-10-26 Biontech Rna Pharmaceuticals Gmbh Procédés de production d'arn simple brin
CN106191036A (zh) * 2016-08-08 2016-12-07 吴江近岸蛋白质科技有限公司 Rna结合蛋白在提取核酸中的应用及提取方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A multilingual glossary of biotechnological terms: (IUPAC Recommendations", 1995, HELVETICA CHIMICA ACTA
DUCHANGE NATHALIE ET AL: "Alternative splicing in the human interleukin enhancer binding factor 3 (ILF3) gene", GENE, vol. 261, no. 2, 1 December 2000 (2000-12-01), NL, pages 345 - 353, XP093345042, ISSN: 0378-1119, DOI: 10.1016/S0378-1119(00)00495-9 *
THOMPSON ET AL., NUCLEIC ACIDS RES., vol. 22, no. 22, 1994, pages 4673 - 4680
XIAOQUIN HUANGWEBB MILLER, ADVANCES IN APPLIED MATHEMATICS, vol. 12, 1991, pages 337 - 357

Similar Documents

Publication Publication Date Title
CN107922483B (zh) 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
CN109476712B (zh) 新型对碱稳定的免疫球蛋白结合蛋白
EP1370574B1 (fr) Modules de liaison avec la streptavidine disposes de maniere sequentielle, utilises comme etiquettes d'affinite
CN111132994B (zh) 在c末端螺旋区中具有半胱氨酸的fc结合蛋白
JP5951509B2 (ja) 免疫グロブリンＧＦｃ領域結合ポリペプチド
CN114829379B (zh) 酶酸α葡萄糖苷酶(GAA)的结合蛋白及其用途
JP2019515687A (ja) ストレプトアビジン突然変異タンパク質およびそれらを使用する方法
US20230193239A1 (en) Polynucleotide purification with monolith columns
CN115947862B (zh) Sh2超亲体蛋白及其与固相缀合所形成的缀合物
De Vos et al. Production of full-length SARS-CoV-2 nucleocapsid protein from Escherichia coli optimized by native hydrophobic interaction chromatography hyphenated to multi-angle light scattering detection
US20060105407A1 (en) Protein chip for analyzing interaction between protein and substrate peptide thereof
CN114957415B (zh) 链霉亲和素突变体及其应用和产品、基因、重组质粒和基因工程菌
WO2020211878A1 (fr) Aptamère de nattokinase et procédé de criblage associé
WO2026078207A1 (fr) Nouveaux ligands de liaison à l'arndb et leur utilisation en chromatographie d'affinité
WO2017149002A1 (fr) Nouvelles protéines de fusion pour la capture de cellules
Dangerfield et al. Enhancement of the StreptoTag method for isolation of endogenously expressed proteins with complex RNA binding targets
CN114752600B (zh) 组氨酸标签的核酸适配体
US20230093429A1 (en) AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (sFGFR3)
WO2025256020A1 (fr) Système de protéine à ultra-haute affinité et son utilisation
WO2025256022A1 (fr) Protéine immunitaire de pseudomonas aeruginosa et son utilisation
De Vos et al. Native Hydrophobic Interaction Chromatography Hyphenated to Multi-Angle Light Scattering Detection for In-Process Control of SARS-CoV-2 Nucleocapsid Protein Produced in Escherichia Coli
Sripinitchai et al. Novel nuclease-resistant RNA aptamer for polyhistidine-tagged proteins and its application in electrochemical aptasensor detection
JP5055551B2 (ja) タンパク等の分離・検出方法
CN103282493A (zh) 修饰型tamavidin
JPWO2005012902A1 (ja) 有用タンパク質のスクリーニング方法